Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years - Nicholas J. Robert, M.D (Co-Author)
Jun 7, 2016
Announcement Virginia Cancer Specialists: Phycisian Nicholas J. Robert, M.D, featured as co-author in the New England Journal of Medicine
Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor–positive early breast cancer in postmenopausal women. Extending treatment with an aromatase inhibitor to 10 years may further reduce the risk of breast-cancer re-currence.